Chimeric AAV Capsids for Retrograde Neuron Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches for Parkinson's disease lack specificity in targeting dopamine receptors, leading to non-specific treatment effects due to wide distribution in the central nervous system and periphery, and existing AAV vectors have limited infectivity in neuronal cells, particularly medium spiny neurons.
Innovation Solution
Development of chimeric AAV2 and AAV8 viruses with variant capsid polypeptides, including specific amino acid alterations, to enhance infectivity and enable retrograde transport to dopaminergic medium spiny neurons, combined with designer receptors activated by designer drugs (DREADD) for precise therapeutic modulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional AAV vectors are used for gene therapy delivery, then the vectors can establish latent infection and avoid destructive immune response, but the infectivity in neuronal cells particularly medium spiny neurons is limited
Solution Approach 1:
The patent applies local quality by creating serotype-specific capsid variants (AAV2 and AAV8) with tailored amino acid sequences that are optimized for specific neuronal cell types. The capsid proteins contain specific amino acid alterations (e.g., V125I, V183E, N411S, Y447F, R490Q, T495A, F536Y, A606S) that enable selective binding to receptors expressed on medium spiny neurons, thereby achieving cell-type-specific infectivity while maintaining the overall safety profile of AAV vectors.
Solution Approach 2:
The patent employs parameter changes by modifying the capsid protein amino acid sequence at specific positions to alter the vector's biological properties. These parameter alterations in the capsid structure change the receptor binding specificity and cellular tropism of the AAV vector, transforming it from a generic vector into a serotype-specific tool that preferentially infects medium spiny neurons while maintaining latent infection characteristics.
2Reliability
If dopamine receptor agonists are used to treat Parkinson's disease, then the symptoms can be managed, but the action lacks specificity due to wide distribution of dopamine receptors in the central nervous system and periphery
Solution Approach 1:
The patent applies local quality by delivering gene therapy specifically to medium spiny neurons in the striatum, which are the neuronal population responsible for motor control and dopamine signaling in Parkinson's disease. The serotype-specific AAV vectors ensure that the therapeutic gene expression is localized to this specific cell type, avoiding off-target effects in other dopamine-receptor-expressing tissues while maintaining therapeutic efficacy.
Solution Approach 2:
The patent uses an intermediary approach by introducing designer receptors exclusively activated by designer drugs (DREADDs) as a mediator between the AAV vector and the therapeutic outcome. The DREADDs serve as a controllable intermediary that can be selectively activated by administered ligands to manipulate neuronal activity in medium spiny neurons, providing precise control over therapeutic effects without requiring direct modification of endogenous dopamine receptors.
3Measurement precision
If retrograde AAV vectors are developed to target medium spiny neurons, then the infectivity and targeting precision improve, but the complexity of the viral vector system increases
Solution Approach 1:
The patent applies segmentation by dividing the AAV capsid protein into functional domains and identifying specific amino acid positions that can be independently mutated to achieve desired tropism. The capsid variants are constructed by combining specific amino acid alterations at defined positions (V125, V183, N411, Y447, R490, T495, F536, A606), allowing modular assembly of functional elements without requiring complete redesign of the entire capsid structure.
Solution Approach 2:
The patent employs composite materials by creating chimeric capsid proteins that combine features from different AAV serotypes (AAV2 and AAV8) to achieve optimal properties. The capsid variants integrate conserved structural elements from parent serotypes with specific amino acid alterations that confer enhanced retrograde transport and medium spiny neuron specificity, resulting in a composite viral particle with tailored biological properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified AAV vectors demonstrate significantly increased infectivity and specificity in targeting medium spiny neurons, effectively rescuing locomotion and motor skills in Parkinson's disease models, supporting targeted circuit modulation for therapeutic efficacy.
Implementation Method 1
the variant capsid polypeptide comprises an alteration to increase retrograde transport of the rAAV virion by an axon of a neuron
Data Source
AI summary
The present invention provides for recombinant adeno-associated virus (rAAV) virions comprising a variant capsid polypeptide, wherein the variant capsid polypeptide comprises an alteration to an amino acid corresponding to an adeno-associated virus (AAV) capsid polypeptide amino acid selected from the list consisting of any one or more of V125, V183, N411, Y447, R490, T495, and F536 of SEQ ID NO: 1; and wherein the variant capsid polypeptide comprises an alteration to increase retrograde transport of the rAAV virion by an axon of a neuron. The present invention also provides for recombinant adeno-associated virus (rAAV) variant capsid polypeptides, wherein the variant capsid polypeptide comprises an alteration to an amino acid corresponding to an adeno-associated virus (AAV) capsid polypeptide amino acid selected from the list consisting of any one or more of V125, V183, N411, Y447, R490, T495, and F536 of SEQ ID NO: 1.